• 1
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 7196.
  • 2
    Anderson KE, Mack TM, Silverman DT. Cancer of the pancreas. In: SchottenfeldD, FraumeniJFJr, eds. Cancer epidemiology and prevention, 3rd ed. New York: Oxford University Press, 2006. 72162.
  • 3
    Duell EJ, Bracci PM, Holly EA. Environmental determinants of exocrine pancreatic cancer. In: PourPM, ed. Toxicology of the pancreas. Boca Raton: CRC Press, 2006. 395422.
  • 4
    Benz C, Hollander C, Miller B. Endocrine-responsive pancreatic carcinoma: steroid binding and cytotoxicity studies in human tumor cell lines. Cancer Res 1986; 46: 227681.
  • 5
    Bourhis J, Lacaine F, Augusti M, Huguier M. Protective effect of oestrogen in pancreatic cancer. Lancet 1987; 2( 8565): 977.
  • 6
    Longnecker DS, Sumi C. Effects of sex steroid hormones on pancreatic cancer in the rat. Int J Pancreatol 1990; 7: 15965.
  • 7
    Longnecker DS. Hormones and pancreatic cancer. Int J Pancreatol 1991; 9: 816.
  • 8
    Adami HO, Persson I, Hoover R, Schairer C, Bergkvist L. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 1989; 44: 8339.
  • 9
    Bueno de Mesquita HB, Maisonneuve P, Moerman CJ, Walker AM. Anthropometric and reproductive variables and exocrine carcinoma of the pancreas: a population-based case-control study in The Netherlands. Int J Cancer 1992; 52: 249.
  • 10
    Cantor KP, Lynch CF, Johnson D. Reproductive factors and risk of brain, colon, and other malignancies in Iowa (United States). Cancer Causes Control 1993; 4: 50511.
  • 11
    Duell EJ, Holly EA. Reproductive and menstrual risk factors for pancreatic cancer: a population-based study of San Francisco Bay Area women. Am J Epidemiol 2005; 161: 7417.
  • 12
    Fernandez E, La Vecchia C, d'Avanzo B, Negri E. Menstrual and reproductive factors and pancreatic cancer risk in women. Int J Cancer 1995; 62: 114.
  • 13
    Fernandez E, Gallus S, Bosetti C, Franceschi S, Negri E, La Vecchia C. Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int J Cancer 2003; 105: 40812.
  • 14
    Haines AP, Moss AR, Whittemore A, Quivey J. A case-control study of pancreatic carcinoma. J Cancer Res Clin Oncol 1982; 103: 937.
  • 15
    Heuch I, Jacobsen BK, Albrektsen G, Kvale G. Reproductive factors and pancreatic cancer risk: a Norwegian cohort study. Br J Cancer 2008; 98: 18993.
  • 16
    Ji BT, Hatch MC, Chow WH, McLaughlin JK, Dai Q, Howe GR, Gao YT, Fraumeni JFJr. Anthropometric and reproductive factors and the risk of pancreatic cancer: a case-control study in Shanghai. China. Int J Cancer 1996; 66: 4327.
  • 17
    Kalapothaki V, Tzonou A, Hsieh CC, Toupadaki N, Karakatsani A, Trichopoulos D. Tobacco, ethanol, coffee, pancreatitis, diabetes mellitus, and cholelithiasis as risk factors for pancreatic carcinoma. Cancer Causes Control 1993; 4: 37582.
  • 18
    Karlson BM, Wuu J, Hsieh CC, Lambe M, Ekbom A. Parity and the risk of pancreatic cancer: a nested case-control study. Int J Cancer 1998; 77: 2247.
  • 19
    Kreiger N, Lacroix J, Sloan M. Hormonal factors and pancreatic cancer in women. Ann Epidemiol 2001; 11: 5637.
  • 20
    Kvale G, Heuch I, Nilssen S. Parity in relation to mortality and cancer incidence: a prospective study of Norwegian women. Int J Epidemiol 1994; 23: 6919.
  • 21
    La Vecchia C, Negri E, Franceschi S, Parazzini F. Long-term impact of reproductive factors on cancer risk. Int J Cancer 1993; 53: 2159.
  • 22
    Lin RS, Kessler II. A multifactorial model for pancreatic cancer in man. Epidemiologic evidence. JAMA 1981; 245: 14752.
  • 23
    Lin Y, Kikuchi S, Tamakoshi A, Kawamura T, Inaba Y, Kurosawa M, Motohashi Y, Yagyu K, Obata Y, Ishibashi T. Association of menstrual and reproductive factors with pancreatic cancer risk in women: findings of the Japan Collaborative Cohort Study for Evaluation of Cancer Risk. J Gastroenterol 2006; 41: 87883.
  • 24
    Lo AC, Soliman AS, El Ghawalby N, Abdel-Wahab M, Fathy O, Khaled HM, Omar S, Hamilton SR, Greenson JK, Abbruzzese JL. Lifestyle, occupational, and reproductive factors in relation to pancreatic cancer risk. Pancreas 2007; 35: 1209.
  • 25
    Mack TM, Yu MC, Hanisch R, Henderson BE. Pancreas cancer and smoking, beverage consumption, and past medical history. J Natl Cancer Inst 1986; 76: 4960.
  • 26
    Navarro Silvera SA, Miller AB, Rohan TE. Hormonal and reproductive factors and pancreatic cancer risk: a prospective cohort study. Pancreas 2005; 30: 36974.
  • 27
    Prizment AE, Anderson KE, Hong CP, Folsom AR. Pancreatic cancer incidence in relation to female reproductive factors: Iowa Women's Health Study. JOP 2007; 8: 1627.
  • 28
    Skinner HG, Michaud DS, Colditz GA, Giovannucci EL, Stampfer MJ, Willett WC, Fuchs CS. Parity, reproductive factors, and the risk of pancreatic cancer in women. Cancer Epidemiol Biomarkers Prev 2003; 12: 4338.
  • 29
    Teras LR, Patel AV, Rodriguez C, Thun MJ, Calle EE. Parity, other reproductive factors, and risk of pancreatic cancer mortality in a large cohort of U.S. women (United States). Cancer Causes Control 2005; 16: 103540.
  • 30
    Wynder EL, Mabuchi K, Maruchi N, Fortner JG. A case control study of cancer of the pancreas. Cancer 1973; 31: 6418.
  • 31
    Sharp L, Cardy AH, Cotton SC, Little J. CYP17 gene polymorphisms: prevalence and associations with hormone levels and related factors: a HuGE review. Am J Epidemiol 2004; 160: 72940.
  • 32
    Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, Franks S, Williamson R. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994; 3: 18736.
  • 33
    Nedelcheva KV, Haraldsen EK, Anderson KB, Lonning PE, Erikstein B, Karesen R, Gabrielsen OS, Borresen-Dale AL. CYP17 and breast cancer risk: the polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1. Cancer Res 1999; 59: 28258.
  • 34
    Olson SH, Bandera EV, Orlow I. Variants in estrogen biosynthesis genes, sex steroid hormone levels, and endometrial cancer: a HuGE review. Am J Epidemiol 2007; 165: 23545.
  • 35
    Feigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ, Henderson BE. Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 1998; 58: 5857.
  • 36
    Setiawan VW, Schumacher FR, Haiman CA, Stram DO, Albanes D, Altshuler D, Berglund G, Buring J, Calle EE, Clavel-Chapelon F, Cox DG, Gaziano JM, et al. CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev 2007; 16: 223746.
  • 37
    Tworoger SS, Chubak J, Aiello EJ, Ulrich CM, Atkinson C, Potter JD, Yasui Y, Stapleton PL, Lampe JW, Farin FM, Stanczyk FZ, McTiernan A. Association of CYP17. CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2004; 13: 94101.
  • 38
    Chen Y, Gammon MD, Teitelbaum SL, Britton JA, Terry MB, Shantakumar S, Eng SM, Wang Q, Gurvich I, Neugut AI, Santella RM, Ahsan H. Estrogen-biosynthesis gene CYP17 and its interactions with reproductive, hormonal and lifestyle factors in breast cancer risk: results from the Long Island Breast Cancer Study Project. Carcinogenesis 2008; 29: 76671.
  • 39
    Feigelson HS, Coetzee GA, Kolonel LN, Ross RK, Henderson BE. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res 1997; 57: 10635.
  • 40
    Feigelson HS, McKean-Cowdin R, Henderson BE. Concerning the CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis 2002; 17: 4456.
  • 41
    Gaudet MM, Lacey JVJr, Lissowska J, Peplonska B, Brinton LA, Chanock S, Garcia-Closas M. Genetic variation in CYP17 and endometrial cancer risk. Hum Genet 2008; 123: 15562.
  • 42
    Ntais C, Polycarpou A, Ioannidis JP. Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2003; 12: 1206.
  • 43
    Sarma AV, Dunn RL, Lange LA, Ray A, Wang Y, Lange EM, Cooney KA. Genetic polymorphisms in CYP17. CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in. African-American men: the Flint Men's Health Study. Prostate 2008; 68: 296305.
  • 44
    Chan JM, Wang F, Holly EA. Vegetable and fruit intake and pancreatic cancer in a population-based case-control study in the San Francisco bay area. Cancer Epidemiol Biomarkers Prev 2005; 14: 20937.
  • 45
    Chan JM, Wang F, Holly EA. Whole grains and risk of pancreatic cancer in a large population-based case-control study in the San Francisco Bay Area. California. Am J Epidemiol 2007; 166: 117485.
  • 46
    Chan JM, Wang F, Holly EA. Pancreatic cancer, animal protein and dietary fat in a population-based study: San Francisco Bay Area California. Cancer Causes Control 2007; 18: 115367.
  • 47
    Eberle CA, Bracci PM, Holly EA. Anthropometric factors and pancreatic cancer in a population-based case-control study in the San Francisco Bay area. Cancer Causes Control 2005; 16: 123544.
  • 48
    Holly EA, Eberle CA, Bracci PM. Prior history of allergies and pancreatic cancer in the San Francisco Bay area. Am J Epidemiol 2003; 158: 43241.
  • 49
    Wang F, Gupta S, Holly EA. Diabetes mellitus and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area. California. Cancer Epidemiol Biomarkers Prev 2006; 15: 145863.
  • 50
    Duell EJ, Holly EA, Bracci PM, Liu M, Wiencke JK, Kelsey KT. A population-based, case-control study of polymorphisms in carcinogen-metabolizing genes, smoking, and pancreatic adenocarcinoma risk. J Natl Cancer Inst 2002; 94: 297306.
  • 51
    Duell EJ, Casella DP, Burk RD, Kelsey KT, Holly EA. Inflammation, genetic polymorphisms in proinflammatory genes TNF-A. RANTES, and CCR5, and risk of pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2006; 15: 72631.
  • 52
    Duell EJ, Bracci PM, Moore JH, Burk RD, Kelsey KT, Holly EA. Detecting pathway-based gene-gene and gene-environment interactions in pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 14709.
  • 53
    Duell EJ, Holly EA, Bracci PM, Wiencke JK, Kelsey KT. A population-based study of the Arg399Gln polymorphism in X-Ray Repair Cross-Complementing Group 1 (XRCC1) and risk of pancreatic adenocarcinoma. Cancer Res 2002; 62: 46306.
  • 54
    Henningson M, Johansson U, Borg A, Olsson H, Jernstrom H. CYP17 genotype is associated with short menstrual cycles, early oral contraceptive use and BRCA mutation status in young healthy women. Mol Hum Reprod 2007; 13: 2316.
  • 55
    Jasienska G, Kapiszewska M, Ellison PT, Kalemba-Drozdz M, Nenko I, Thune I, Ziomkiewicz A. CYP17 genotypes differ in salivary 17-beta estradiol levels: a study based on hormonal profiles from entire menstrual cycles. Cancer Epidemiol Biomarkers Prev 2006; 15: 21315.
  • 56
    Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004; 96: 43442.
  • 57
    Wu AH, Seow A, Arakawa K, Van Den BD, Lee HP, Yu MC. HSD17B1 and CYP17 polymorphisms and breast cancer risk among Chinese women in Singapore. Int J Cancer 2003; 104: 4507.
  • 58
    Lindstrom S, Zheng SL, Wiklund F, Jonsson BA, Adami HO, Balter KA, Brookes AJ, Sun J, Chang BL, Liu W, Li G, Isaacs WB, et al. Systematic replication study of reported genetic associations in prostate cancer: strong support for genetic variation in the androgen pathway. Prostate 2006; 66: 172943.
  • 59
    Basu A, Castle VP, Bouziane M, Bhalla K, Haldar S. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family. Cancer Res 2006; 66: 430918.